UNSPSC 51434919: Captopril/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434919 Captopril/hydrochlorothiazide is a Commodity code that in practice captures state and local procurement of emergency and clinical medications, with recent solicitations reflecting demand for advanced life support drugs, generic pharmaceuticals supplied through cooperative purchasing arrangements, and pharmacy benefit program administration across state health systems. The City of Tampa's recent sealed-bid procurement for Tampa Fire Rescue sought Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem—drugs used in emergency response rather than the specific code name alone—signaling that state and local bodies tag broader medication categories under this Commodity code. Issuing bodies include municipal fire and rescue departments, state health agencies, and cooperative purchasing alliances serving multi-state networks of public facilities. The Texas Health and Human Services Commission's concurrent RFI on direct-to-manufacturer prescription fulfillment indicates state-level policy-driven procurement of pharmaceutical supply-chain services, alongside traditional product purchasing.

Activity appears concentrated in Florida and Minnesota, with Texas engagement at the exploratory stage. The City of Tampa issued IFB 26P00188 on April 24, 2026, with a due date of April 8, 2026 (a historical date relative to today's 2026-07-20 reference), for Advanced Life Support Medications with an estimated contract value of $40,000, firm pricing including freight to Tampa, nine-month minimum expiration from acceptance, one-year initial term with two optional renewals, and a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, for Generic Multi-Source Pharmaceuticals and OTC Products with a March 26, 2026 response deadline, requiring NDC-level product detail, pricing through three authorized wholesalers, cGMP and Drug Supply Chain Security Act compliance, and a two-year initial contract term. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) sought vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer program outside traditional PBM and GPO channels, with no disclosed budget or formal evaluation criteria—a preliminary market intelligence tool preceding formal procurement.